Genentech reports Phase II bladder cancer data

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said atezolizumab (anti-PDL1, MPDL3280A, RG7446) met the primary endpoint of overall response rate in a cohort of patients in the Phase II IMvigor 210 trial to treat urothelial bladder cancer. Genentech also said high PD-L1 expression correlated with patient response to the human mAb against PD-L1.

The single-arm study enrolled a total of 439 patients regardless of their PD-L1 expression. Monday's results were from a cohort of patients who had progressed after receiving platinum-based chemotherapy. Genentech said data are not yet mature from the study's other cohort, which includes previously untreated patients who are ineligible for first-line cisplatin-based therapy. ...